{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:36:58Z","timestamp":1714696618205},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"DOI":"10.7759\/cureus.59541","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:46:17Z","timestamp":1714686377000},"source":"Crossref","is-referenced-by-count":0,"title":["Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia"],"prefix":"10.7759","author":[{"given":"Sasikanth N","family":"Ravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene W","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva K","family":"Ngapgue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda G","family":"Stroiney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive J","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9 SE","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR, et al.. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015, 56:2779-2786. 10.3109\/10428194.2015.1022770","journal-title":"Leuk Lymphoma"},{"key":"ref2","unstructured":"U.S. Food and Drug Administration. Label for ZYDELIG (idelalisib), NDA 205858. (2018). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205858s009lbl.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman RR","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, et al.. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014, 370:997-1007. 10.1056\/NEJMoa1315226","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal AK","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, et al.. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014, 370:1008-1018. 10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.3.785","article-title":"Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes","volume":"122","author":"Helman DL Jr","year":"2002","unstructured":"Helman DL Jr, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest. 2002, 122:785-790. 10.1378\/chest.122.3.785","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.888056","article-title":"Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms","volume":"13","author":"Duran I","year":"2014","unstructured":"Duran I, Goebell PJ, Papazisis K, Ravaud A, Weichhart T, Rodriguez-Portal JA, Budde K. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf. 2014, 13:361-372. 10.1517\/14740338.2014.888056","journal-title":"Expert Opin Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.5_suppl.401","article-title":"Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in patients with metastatic renal cell cancer (mRCC): A single-center experience","volume":"5","author":"Cauley DH","year":"201230","unstructured":"Cauley DH, Atkinson BJ, Ng CS, et al.. Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in patients with metastatic renal cell cancer (mRCC): A single-center experience. J Clin Oncol. 201230, 5:401. 10.1200\/jco.2012.30.5_suppl.401","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds115","article-title":"Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma","volume":"23","author":"Albiges L","year":"2012","unstructured":"Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol. 2012, 23:1943-1953. 10.1093\/annonc\/mds115","journal-title":"Ann Oncol"},{"key":"ref9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, National Institutes of Health, National Cancer Institute. (2017). https.\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S73530","article-title":"Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas","volume":"6","author":"Madanat YF","year":"2016","unstructured":"Madanat YF, Smith MR, Almasan A, Hill BT. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer. 2016, 6:1-6. 10.2147\/BLCTT.S73530","journal-title":"Blood Lymphat Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2004.05.006","article-title":"Drug-induced and iatrogenic infiltrative lung disease","volume":"25","author":"Camus P","year":"2004","unstructured":"Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med. 2004, 25:479-519. 10.1016\/j.ccm.2004.05.006","journal-title":"Clin Chest Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.608625","article-title":"The pi3k\u2202-selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of B-cell malignancy-associated immunosuppression","volume":"12","author":"Rohrbacher L","year":"2021","unstructured":"Rohrbacher L, Brauchle B, Ogrinc Wagner A, von Bergwelt-Baildon M, B\u00fccklein VL, Subklewe M. The pi3k\u2202-selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of B-cell malignancy-associated immunosuppression. Front Immunol. 2021, 12:608625. 10.3389\/fimmu.2021.608625","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/215792-idelalisib-induced-pneumonitis-in-chronic-lymphocytic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:46:22Z","timestamp":1714686382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/215792-idelalisib-induced-pneumonitis-in-chronic-lymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.59541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}